Salvatore Zarrella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salvatore Zarrella has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Bertamino
Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy
1 shared publication - Giacomo Pepe
Department of Pharmacy University of Salerno Fisciano (SA) Italy
1 shared publication - Ignazio Restivo
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Via Archirafi 28, 90123 Palermo, Italy
1 shared publication - Luisa Tesoriere
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Via Archirafi 28, 90123 Palermo, Italy
1 shared publication - Manuela Rodriquez
Department of Pharmacy, University of Naples Federico II, via Domenico Montesano, 49, 80131 Napoli, Italy
1 shared publication - Maria Rosaria Miranda
Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy
1 shared publication
Latest Publications
- Open Access
- 24 March 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (4) , 221
Endoplasmic Reticulum Stress and Its Role in Metabolic Reprogramming of Cancer
Background/Objectives: Endoplasmic reticulum (ER) stress occurs when ER homeostasis is disrupted, leading to the accumulation of misfolded or unfolded proteins. This condition activates the unfolded protein response (UPR), which aims to restore balance or trigger cell death if homeostasis cannot be achieved. In cancer, ER stress plays a key role due to the heightened metabolic demands of tumor cells. This review explores how metabolomics can provide insights into ER stress-related metabolic alterations and their implications for cancer therapy. Methods: A comprehensive literature review was conducted to analyze recent findings on ER stress, metabolomics, and cancer metabolism. Studies examining metabolic profiling of cancer cells under ER stress conditions were selected, with a focus on identifying potential biomarkers and therapeutic targets. Results: Metabolomic studies highlight significant shifts in lipid metabolism, protein synthesis, and oxidative stress management in response to ER stress. These metabolic alterations are crucial for tumor adaptation and survival. Additionally, targeting ER stress-related metabolic pathways has shown potential in preclinical models, suggesting new therapeutic strategies. Conclusions: Understanding the metabolic impact of ER stress in cancer provides valuable opportunities for drug development. Metabolomics-based approaches may help identify novel biomarkers and therapeutic targets, enhancing the effectiveness of antitumor therapies.
- 24 March 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (4) , 221
Open AccessEndoplasmic Reticulum Stress and Its Role in Metabolic Reprogramming of Cancer
Background/Objectives: Endoplasmic reticulum (ER) stress occurs when ER homeostasis is disrupted, leading to the accumulation of misfolded or unfolded proteins. This condition activates the unfolded protein response (UPR), which aims to restore balance or trigger cell death if homeostasis cannot be achieved. In cancer, ER stress plays a key role due to the heightened metabolic demands of tumor cells. This review explores how metabolomics can provide insights into ER stress-related metabolic alterations and their implications for cancer therapy. Methods: A comprehensive literature review was conducted to analyze recent findings on ER stress, metabolomics, and cancer metabolism. Studies examining metabolic profiling of cancer cells under ER stress conditions were selected, with a focus on identifying potential biomarkers and therapeutic targets. Results: Metabolomic studies highlight significant shifts in lipid metabolism, protein synthesis, and oxidative stress management in response to ER stress. These metabolic alterations are crucial for tumor adaptation and survival. Additionally, targeting ER stress-related metabolic pathways has shown potential in preclinical models, suggesting new therapeutic strategies. Conclusions: Understanding the metabolic impact of ER stress in cancer provides valuable opportunities for drug development. Metabolomics-based approaches may help identify novel biomarkers and therapeutic targets, enhancing the effectiveness of antitumor therapies.